Group One Trading’s Fate Therapeutics FATE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $600 | Sell |
500
-8,500
| -94% | -$10.3K | ﹤0.01% | 7299 |
|
|
2025
Q4 | $8.84K | Sell |
9,000
-11,200
| -55% | -$13.4K | ﹤0.01% | 6876 |
|
|
2025
Q3 | $25.5K | Sell |
20,200
-2,500
| -11% | -$2.7K | ﹤0.01% | 6516 |
|
|
2025
Q2 | $25.4K | Buy |
22,700
+20,200
| +808% | +$23.5K | ﹤0.01% | 6108 |
|
|
2025
Q1 | $1.98K | Sell |
2,500
-5,500
| -69% | -$6.74K | ﹤0.01% | 7007 |
|
|
2024
Q4 | $13.2K | Buy |
+8,000
| New | +$20.2K | ﹤0.01% | 5952 |
|
|
2024
Q2 | – | Sell |
-4,600
| Closed | -$33.8K | – | 6945 |
|
|
2024
Q1 | $33.8K | Buy |
+4,600
| New | +$28.5K | ﹤0.01% | 5030 |
|
|
2023
Q4 | – | Sell |
-6,000
| Closed | -$12.7K | – | 7601 |
|
|
2023
Q3 | $12.7K | Buy |
6,000
+2,900
| +94% | +$9.61K | ﹤0.01% | 6198 |
|
|
2023
Q2 | $14.8K | Buy |
3,100
+100
| +3% | +$552 | ﹤0.01% | 6177 |
|
|
2023
Q1 | $17.1K | Sell |
3,000
-200
| -6% | -$1.21K | ﹤0.01% | 5613 |
|
|
2022
Q4 | $32.3K | Sell |
3,200
-6,300
| -66% | -$118K | ﹤0.01% | 5292 |
|
|
2022
Q3 | $213K | Sell |
9,500
-4,100
| -30% | -$118K | ﹤0.01% | 4077 |
|
|
2022
Q2 | $337K | Sell |
13,600
-2,200
| -14% | -$60.7K | ﹤0.01% | 3796 |
|
|
2022
Q1 | $613K | Sell |
15,800
-15,300
| -49% | -$592K | ﹤0.01% | 3599 |
|
|
2021
Q4 | $1.82M | Sell |
31,100
-3,100
| -9% | -$176K | ﹤0.01% | 2709 |
|
|
2021
Q3 | $2.03M | Buy |
34,200
+28,500
| +500% | +$2.24M | ﹤0.01% | 2632 |
|
|
2021
Q2 | $495K | Buy |
5,700
+3,900
| +217% | +$314K | ﹤0.01% | 4234 |
|
|
2021
Q1 | $148K | Buy |
1,800
+900
| +100% | +$86.2K | ﹤0.01% | 5292 |
|
|
2020
Q4 | $82K | Buy |
+900
| New | +$55.9K | ﹤0.01% | 4697 |
|
|
2020
Q3 | – | Sell |
-34,500
| Closed | -$1.18M | – | 6216 |
|
|
2020
Q2 | $1.18M | Buy |
34,500
+12,800
| +59% | +$381K | 0.01% | 1878 |
|
|
2020
Q1 | $482K | Buy |
21,700
+16,900
| +352% | +$427K | ﹤0.01% | 2076 |
|
|
2019
Q4 | $94K | Buy |
4,800
+1,800
| +60% | +$28.6K | ﹤0.01% | 3675 |
|
|
2019
Q3 | $47K | Buy |
3,000
+2,000
| +200% | +$38.3K | ﹤0.01% | 3997 |
|
|
2019
Q2 | $20K | Sell |
1,000
-13,600
| -93% | -$245K | ﹤0.01% | 4178 |
|
|
2019
Q1 | $257K | Sell |
14,600
-11,600
| -44% | -$183K | ﹤0.01% | 2514 |
|
|
2018
Q4 | $336K | Buy |
26,200
+11,900
| +83% | +$166K | ﹤0.01% | 2280 |
|
|
2018
Q3 | $233K | Sell |
14,300
-30,700
| -68% | -$363K | ﹤0.01% | 2906 |
|
|
2018
Q2 | $510K | Buy |
45,000
+22,300
| +98% | +$246K | ﹤0.01% | 2272 |
|
|
2018
Q1 | $222K | Buy |
+22,700
| New | +$217K | ﹤0.01% | 2715 |
|
Other funds holding FATE
RG
VCM
VPM
JJ
Group One Trading's FATE Position: Q1 2026 in Review
Group One Trading increased its Fate Therapeutics (FATE) stake by 110% in Q1 2026, buying an estimated $5.93K and bringing the position to 9,305 shares worth $11.2K. The position accounts for ﹤0.01% of the portfolio, ranked #6317.
Group One Trading first reported a position in FATE in Q2 2018 and has held it in 22 quarters since. The position peaked at $585K in Q1 2020. 157 funds tracked by Wall St. Rank hold FATE as of Q1 2026.
- Group One Trading held 9,305 shares of Fate Therapeutics worth $11.2K as of Q1 2026.
- Group One Trading bought 4,874 Fate Therapeutics shares in Q1 2026, an estimated $5.93K.
- Fate Therapeutics made up ﹤0.01% of Group One Trading's portfolio in Q1 2026, its #6317 holding.
- Group One Trading first reported a position in Fate Therapeutics in Q2 2018 and has held it in 22 quarters since.
- Group One Trading's Fate Therapeutics position peaked at $585K in Q1 2020.
- 157 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2026.
Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.